The hurdles of nanotoxicity in transplant nanomedicine

In this review, researchers from the Office of Science & Technology (TX, USA) evaluate the toxicological profiles of immunosuppressant therapies and their conversion into nanomedicine formulations.

Go to the profile of Nanomedicine
Nov 20, 2019
0
0

Nanomedicine has matured significantly in the past 20 years and a number of nanoformulated therapies are cleared by regulatory agencies for use across the globe. Transplant medicine is one area that has significantly benefited from the advancement of nanomedicine in recent times. However, while nanoparticle-based therapies have improved toxicological profiles of some drugs, there are still a number of aspects regarding the biocompatibility and toxicity of nanotherapies that require further research.

In this review, researchers from the Office of Science & Technology (TX, USA) evaluate the toxicological profiles of immunosuppressant therapies and their conversion into nanomedicine formulations, as well as introduce future challenges associated with current in vitro and in vivo toxicological models.

Read the full open-access review in Nanomedicine, for free, now >>

Go to the profile of Nanomedicine

Nanomedicine

Journal, Future Science Group

Nanomedicine (Impact Factor: 4.717 [2018), is an award-winning peer-reviewed journal from Future Science Group, available in both print and online formats. Published 24 times per year, Nanomedicine is a uniquely medicine-focused journal, addressing the important challenges and advances in medical nanoscale-structured material and devices, biotechnology devices and molecular machine systems and nanorobotics, delivering this essential information in concise, clear and attractive article formats. Nanomedicine is listed by Medline/PubMed, Science Citation Index Expanded, Journal Citation Reports/Science Edition, Current Contents/Life Sciences and the Biotechnology Citation Index. Professor Kostas Kostarelos (Nanomedicine Lab, University of Manchester, UK) is the journal’s Senior Editor. You can find out more about Nanomedicine on our website (http://www.futuremedicine.com/loi/nnm), including the journal’s aims and scope and details of our international editorial board.

No comments yet.